Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer

British Journal of Cancer

Volumn 103, Issue 8, 2010, Pages 1284-1291

  Godinho, M F E ^a   Sieuwerts, A M ^a   Look, M P ^a   Meijer, D ^a   Foekens, J A ^a   Dorssers, L C J ^a   Van Agthoven, T ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

BCAR4; endocrine therapy; ERBB2; ERBB3; ERBB4; tamoxifen resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BCAR4 NON-CODING RNA, HUMAN; CRK ASSOCIATED SUBSTRATE PROTEIN; LONG UNTRANSLATED RNA; PHARMACOLOGICAL BIOMARKER; SIGNAL TRANSDUCING ADAPTOR PROTEIN; UNTRANSLATED RNA;

ADULT; AGED; ARTICLE; BREAST CANCER; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RNA INTERFERENCE; SURVIVAL; BREAST NEOPLASMS; CARCINOMA; DRUG RESISTANCE; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; TUMOR CELL LINE; TUMOR INVASION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CRK-ASSOCIATED SUBSTRATE PROTEIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAMOXIFEN; RNA, LONG NONCODING; RNA, UNTRANSLATED;

EID: 77957999162     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605884     Document Type: Article

References (38)

1. Berns EMJJ, Foekens JA, Van Staveren IL, Van Putten WLJ, De Koning HYWCM, Portengen H, Klijn JGM (1995) Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159: 11-18
2. Brinkman A, Van der Flier S, Kok EM, Dorssers LCJ (2000) BCAR1, a human homologue of the adapter protein p130Cas and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 92: 112-120
3. Carraway KL, Price-Schiavi SA, Komatsu M, Jepson S, Perez A, Carraway CA (2001) Muc4/sialomucin complex in the mammary gland and breast cancer. J Mammary Gland Biol Neoplasia 6: 323-337
4. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22: 7316-7339
5. De Koning JP, Schelen AM, Dong F, Van Buitenen C, Burgering BMT, Bos JL, Löwenberg B, Touw IP (1996) Specific involvement of tyrosine 764 of human granulocyte colony-stimulating factor receptor in signal transduction mediated by p145/Shc/GRB2 or p90/GRB2 complexes. Blood 87: 132-140
6. Di Segni A, Farin K, Pinkas-Kramarski R (2008) Identification of nucleolin as new ErbB receptors-interacting protein. PLoS ONE 3: e2310
7. Dorssers LCJ, Van Agthoven T, Brinkman A (1995) Involvement of genetic alterations in breast tumour progression to hormone independence in vitro. Endocrine Related Cancer 2: 123-126
8. Dorssers LCJ, Van Agthoven T, Dekker A, Van Agthoven TLA, Kok EM (1993) Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: Identification of bcar-1, a common integration site. Mol Endocrinol 7: 870-878
9. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N, Smith I (2001) HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 61: 8452-8458
10. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467
11. EORTC Breast Cancer Cooperative Group (2000) Manual for Clinical Research and Treatment in Breast Cancer pp. 116-117. Excerpta Medical: Almere, The Netherlands
12. Foekens JA, Portengen H, van Putten WL, Peters HA, Krijnen HL, Alexieva-Figusch J, Klijn JG (1989) Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumour cytosols. Cancer Res 49: 5823-5828
13. Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE (2009) Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumours. Breast Cancer Res 11: R11
14. Funes M, Miller JK, Lai C, Carraway III KL, Sweeney C (2006) The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3. J Biol Chem 281: 19310-19319
15. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG (1991) c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63: 434-438
16. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 39: 1289-1293
17. Holbro T, Civenni G, Hynes NE (2003) The ErbB receptors and their role in cancer progression. Exp Cell Res 284: 99-110
18. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll JS (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456: 663-666
19. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354
20. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN (1995) Use of tamoxifen for breast cancer: Twenty-eight years later. J Clin Oncol 13: 513-529
21. Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE, Dowsett M (2003) Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 9: 524S-532S
22. Jordan VC (1995) Third annual William L McGuire memorial lecture - Studies on the estrogen receptor in breast cancer - 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 36: 267-285
23. Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD (2007) Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 120: 1874-1882
24. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of N.C.I.E.W.G.o.C.D (2006) Reporting recommendations for tumour MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100: 229-235 (Pubitemid 44631925)
25. Meijer D, Van Agthoven T, Bosma PT, Nooter K, Dorssers LCJ (2006) Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells. Mol Cancer Res 4: 379-386
26. Mochizuki S, Okada Y (2007) ADAMs in cancer proliferation and progression. Cancer Sci 95: 621-628
27. Nicholson RI, Gee JM, Knowlden J, McClelland R, Madden TA, Barrow D, Hutcheson I (2003) The biology of antihormone failure in breast cancer. Breast Cancer Res Treat 80(Suppl 1): S29-S34; discussion S35
28. Osborne CK, Shou J, Massarweh S, Schiff R (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11: 865s-8670s
29. Ramsauer VP, Carraway CA, Salas PJ, KL C (2003) Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells. J Biol Chem 278: 30142-30147
30. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH (2007) Pathways to tamoxifen resistance. Cancer Lett 256: 1-24
31. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P (1993) Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 11: 1936-1942
32. Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, Portengen H, Klijn JG, Foekens JA (2005) How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin Cancer Res 11: 7311-7321
33. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1989) Human breast cancer: correlation of relapse and survival with amplification of HER2/neu oncogene. Science 235: 177-182
34. Van Agthoven T, Sieuwerts AM, Meijer-Van Gelder ME, Look MP, Smid M, Veldscholte J, Sleijfer S, Foekens JA, Dorssers LCJ (2009a) Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol 27: 542-549
35. Van Agthoven T, Van Agthoven TLA, Dekker A, Van der Spek PJ, Vreede L, Dorssers LCJ (1998) Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J 17: 2799-2808
36. Van Agthoven T, Van Agthoven TLA, Portengen H, Foekens JA, Dorssers LCJ (1992) Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 52: 5082-5088
37. Van Agthoven T, Veldscholte J, Smid M, Van Agthoven TLA, Vreede L, Broertjes M, De Vries I, De Jong D, Sarwari R, Dorssers LCJ (2009b) Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Res Treat 114: 23-30
38. Wright C, Nicholson S, Angus B, Sainsbury JRC, Farndon J, Cairns J, Harris AL, Horne CHW (1992) Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65: 118-121